Sera Prognostics (SERA) widens Q2 2026 loss but extends cash runway to 2029
Rhea-AI Filing Summary
Sera Prognostics, Inc. reported second quarter 2026 results and business updates. Revenue for the quarter was $30,000, up from $17,000 a year earlier, while total operating expenses were $10.0 million. Net loss was $9.1 million compared with $8.0 million in the prior-year quarter, reflecting higher selling, marketing and general and administrative spending to support commercialization.
The company ended the quarter with $80.3 million in cash, cash equivalents and available-for-sale securities and stated this is expected to fund operations through significant adoption and commercialization milestones through 2029. Highlights included launch of a fourth partnership program for the PreTRM® Test with a state-based initiative and national payer, new Illinois legislation mandating Medicaid coverage for proteomic tests assessing preterm birth risk, additional PRIME trial data and recognitions, progress toward European CE marking with pre-application activities expected in the third quarter and submission in the fourth quarter of 2026, and strengthened commercial leadership and board expertise.
Positive
- Strong liquidity and runway: Cash, cash equivalents and marketable securities totaled $80.3 million, which the company believes will fund operations through key commercialization milestones through 2029.
- Expanded market access and validation: Illinois enacted a Medicaid coverage mandate for proteomic tests assessing preterm birth risk, while PRIME trial data and SMFM recognitions support clinical and economic value of the PreTRM Test.
Negative
- Continuing operating losses and asset decline: Q2 2026 net loss was $9.1 million versus $8.0 million a year earlier, and total assets decreased to $86.7 million from $101.9 million at December 31, 2025, indicating ongoing cash burn.
Filing Explained
At June 30, most of the reported $80.3 million liquidity was marketable securities.
At
The company states that its quarter-end cash, cash equivalents, and available-for-sale securities are expected to fund operations through significant adoption and commercialization milestones through 2029. That statement is a forward-looking expectation tied to the
8-K Event Classification
Key Figures
Key Terms
PreTRM® Test medical
PRIME randomized controlled trial medical
CE marking regulatory
deferred revenue financial
laboratory-developed tests regulatory
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Sera Prognostics (SERA) perform financially in Q2 2026?
What is Sera Prognostics’ (SERA) cash position and runway as of June 30, 2026?
What recent policy developments could impact Sera Prognostics (SERA)?
What clinical evidence updates did Sera Prognostics (SERA) report from the PRIME trial?
What progress has Sera Prognostics (SERA) made toward European commercialization?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 12, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to the extent required by applicable law or regulation or as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Description |
99.1 |
|
Press release dated August 12, 2026. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
SERA PROGNOSTICS, INC. |
|
|
|
|
Date: |
August 12, 2026 |
By: |
/s/ Austin Aerts |
|
|
|
Austin Aerts |
Exhibit 99.1
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2026.
Key Second Quarter and Recent Highlights:
“During the second quarter, we continued to build momentum across the key drivers of long-term adoption, including payer engagement, policy advancement, clinical evidence generation, and organizational strength,” said Zhenya Lindgardt, President and Chief Executive Officer of Sera Prognostics. “The launch of our fourth partnership program, progress in payer engagement, the new Illinois Medicaid coverage law, the publication of compelling PRIME data in first-time mothers, and growing recognition from the maternal-fetal medicine community reinforce our belief that precision, biology-driven pregnancy care can improve outcomes for mothers and babies while creating meaningful value for healthcare systems. While we remain in the early stages of market development, we have been encouraged by the steady month-to-month increase in testing volume following publication of the PRIME study, which we believe reflects growing provider awareness and adoption.”
Second Quarter 2026 Financial Results
Second quarter 2026 revenue was $30,000 compared to $17,000 for the second quarter of 2025.
Total operating expenses were $10.0 million, compared to $9.3 million for the same period in 2025.
Research and development expenses for the second quarter of 2026 were $3.5 million, compared to $3.3 million in the prior-year period, reflecting restructuring-related costs; R&D spending expected to decline in future periods.
Selling, general and administrative expenses for the second quarter of 2026 were $6.5 million, compared to $6.0 million for the prior-year period, reflecting investments in commercial execution, marketing programs and strategic hires.
Net loss for the quarter was $9.1 million, compared to $8.0 million for the second quarter of 2025.
Conference Call Information
Sera Prognostics will host a corresponding conference call and live webcast today to discuss second quarter 2026 operational highlights, financial results and recent business highlights at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/O2ldBxvpPmE
Live audio of the webcast will be available online from the Investors page of the Company’s website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks’ gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, marking the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman’s individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date and time and content of the Company’s quarterly earnings release and conference call; availability of the live audio of the conference call on the Company’s website; advancing implementation, reimbursement readiness, and adoption within priority markets; approximately 50,000 annual Medicaid births in Illinois; presentation of two abstracts from the PRIME randomized controlled trial at the SMFM Global Congress 2026; submission of the Company’s CE marking package in the fourth quarter of 2026; current cash funding operations through significant adoption and commercialization milestones through 2029; growing provider awareness and adoption; and the Company’s strategic directives under the caption “About Sera Prognostics, Inc.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading “Risk Factors” contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Contacts:
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
Media Contact
Nicole Kaplan at Allison Worldwide
sera@allisonworldwide.com
+1 (847) 721-6033
SERA PROGNOSTICS, INC.
Condensed Statements of Operations
(unaudited)
(in thousands, except share and per share data)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenue |
|
$ |
30 |
|
|
$ |
17 |
|
|
$ |
44 |
|
|
$ |
55 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
|
50 |
|
|
|
41 |
|
|
|
92 |
|
|
|
81 |
|
Research and development |
|
|
3,493 |
|
|
|
3,337 |
|
|
|
6,523 |
|
|
|
6,671 |
|
Selling and marketing |
|
|
2,243 |
|
|
|
1,821 |
|
|
|
4,255 |
|
|
|
3,291 |
|
General and administrative |
|
|
4,248 |
|
|
|
4,138 |
|
|
|
8,538 |
|
|
|
8,582 |
|
Total operating expenses |
|
|
10,034 |
|
|
|
9,337 |
|
|
|
19,408 |
|
|
|
18,625 |
|
Loss from operations |
|
|
(10,004 |
) |
|
|
(9,320 |
) |
|
|
(19,364 |
) |
|
|
(18,570 |
) |
Interest expense |
|
|
(2 |
) |
|
|
(2 |
) |
|
|
(4 |
) |
|
|
(6 |
) |
Other income, net |
|
|
867 |
|
|
|
1,276 |
|
|
|
1,830 |
|
|
|
2,343 |
|
Net loss |
|
$ |
(9,139 |
) |
|
$ |
(8,046 |
) |
|
$ |
(17,538 |
) |
|
$ |
(16,233 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.18 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.35 |
) |
|
$ |
(0.36 |
) |
Weighted-average shares outstanding, basic and diluted |
|
|
50,476,874 |
|
|
|
49,066,398 |
|
|
|
50,368,464 |
|
|
|
45,536,846 |
|
SERA PROGNOSTICS, INC.
Condensed Balance Sheets
(unaudited)
(in thousands)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
4,398 |
|
|
$ |
3,944 |
|
Marketable securities |
|
|
42,047 |
|
|
|
35,257 |
|
Accounts receivable |
|
|
10 |
|
|
|
12 |
|
Prepaid expenses and other current assets |
|
|
1,679 |
|
|
|
1,557 |
|
Total current assets |
|
|
48,134 |
|
|
|
40,770 |
|
Property and equipment, net |
|
|
1,422 |
|
|
|
1,149 |
|
Long-term marketable securities |
|
|
33,813 |
|
|
|
56,579 |
|
Intangible assets, net |
|
|
888 |
|
|
|
910 |
|
Other assets |
|
|
2,480 |
|
|
|
2,525 |
|
Total assets |
|
$ |
86,737 |
|
|
$ |
101,933 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,190 |
|
|
$ |
862 |
|
Accrued and other current liabilities |
|
|
2,870 |
|
|
|
3,009 |
|
Finance lease obligation, current portion |
|
|
— |
|
|
|
2 |
|
Deferred revenue |
|
|
20,296 |
|
|
|
20,315 |
|
Total current liabilities |
|
|
24,356 |
|
|
|
24,188 |
|
Operating lease obligation, net of current portion |
|
|
3,001 |
|
|
|
2,337 |
|
Total liabilities |
|
|
27,357 |
|
|
|
26,525 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Common stock, Class A and Class B |
|
|
4 |
|
|
|
4 |
|
Additional paid-in capital |
|
|
388,684 |
|
|
|
386,864 |
|
Accumulated other comprehensive (loss) income |
|
|
(48 |
) |
|
|
262 |
|
Accumulated deficit |
|
|
(329,260 |
) |
|
|
(311,722 |
) |
Total stockholders' equity |
|
|
59,380 |
|
|
|
75,408 |
|
Total liabilities and stockholders' equity |
|
$ |
86,737 |
|
|
$ |
101,933 |
|